Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S, Smith MR, Tombal B, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kakiuchi H, Akiyama M, Li R, Kuss I, Joensuu H, Suzuki H.
Uemura M, et al. Among authors: mizokami a.
Cancer Med. 2024 Nov;13(21):e70029. doi: 10.1002/cam4.70029.
Cancer Med. 2024.
PMID: 39527466
Free PMC article.
Clinical Trial.